Scientists Identify How Young Blood Reverses Aging in Human Skin Cells
A special 3D human skin model was set up in the lab by researchers, who then tested the effects of young blood serum on the skin cells. By itself, the serum had no effect, but when bone marrow cells were added to the experiment, anti-aging signals were detected in the skin.
It appears that the young blood serum interacts with the bone marrow cells in specific ways to roll back time in skin cells. The study was led by scientists from Beiersdorf AG, a skin care company in Germany, who say their findings have huge potential in helping us understand anti-aging mechanisms.
Related:
"The skin, as our largest organ, is a valuable tissue to investigate aging, as first signs of aging are mostly visible, and it reflects the overall human health," write the researchers in their published paper.
The researchers measured DNA methylation and cell proliferation to estimate the biological age of the skin tissue, when treated with either young or aged human serum and bone marrow cells. Sure enough, the young serum seemed to reduce the biological age of the skin.
Other biomarkers of more youthful skin included increased metabolic activity and cell division.
Further analysis identified 55 different proteins that were being produced by the bone marrow in response to the young blood, seven of which are known to be linked to processes important to youthful skin, like cell renewal and collagen production.
These proteins could be key to understanding the effects of the young blood and bone marrow, though there's plenty of work to do yet. Researchers need to get this tested in living humans, not just isolated cells in the lab.
"We identified several proteins that might be responsible factors to rejuvenate the skin in our system," write the researchers.
"Future studies are needed to further validate our identified proteins in the context of systemic skin rejuvenation and aging."
The concept of blood having the power to extend life and restore youth has been around for centuries, inspiring the first vampire tales, but there's an increasing amount of evidence that it could have actual scientific potential.
Multiple studies have shown that some of the wear and tear that comes with getting older may not be a one-way street: we might be able to reprogram the body in various ways that slow down aging or even reverse it.
With the global population getting older and older, we're living longer than ever before, on average – and our bodies aren't necessarily built to stay in good shape for that long. What research like this does is point towards strategies for staying healthier later into life, keeping illness and disease at bay for longer.
"Aging is a complex process that significantly contributes to age-related diseases and poses significant challenges for effective interventions, with few holistic anti-aging approaches successfully reversing its signs," write the researchers.
The research has been published in Aging.
Related News
Vegetarian Diets Can Slash Cancer Risk by Up to 45%, Large Study Finds
'World's Oldest Baby' May Not Be a Record For Long, Says Expert
Targeting a Single Hormone Could Help Treat 40% of IBS-D Cases
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity. The accelerated approval is based on part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo. The clinical data from ESSENCE showed that at week 72, 36.8% of people treated with Wegovy® achieved improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.4% treated with placebo. 62.9% of people treated with Wegovy® achieved resolution of steatohepatitis with no worsening of liver fibrosis compared to 34.3% treated with placebo. 'Wegovy® is now uniquely positioned as the first and only GLP-1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide,' said Martin Holst Lange, executive vice president, chief scientific officer and head of Research and Development, at Novo Nordisk. 'MASH represents a significant health burden, with one in three people with overweight or obesity worldwide affected. In the US alone, around 22 million people are estimated to live with MASH. With the approval of Wegovy® for MASH, we provide a new treatment to people living with MASH that not only halts the disease activity but helps reverse the damage caused to the liver.' As of today, Wegovy® is available in the US for the treatment for MASH. About MASH Metabolic dysfunction-associated steatohepatitis (MASH) is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not properly managed. More than 250 million people live with MASH and the number of individuals in advanced stages of the disease is expected to double by 2030. Of those who are currently overweight or living with obesity, more than one in three are also living with MASH. People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in delayed diagnosis. The risk of progression to advanced liver disease, including liver cancer, is higher in people living with MASH than in the general population. About the ESSENCE trial ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). ESSENCE is a two-part trial where 1,200 planned participants were randomised 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. In part 1, the objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology at 72 weeks based on biopsy sampling from the first 800 randomised patients. In part 2, the objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks. Based on part 1 of the ESSENCE trial, Novo Nordisk has also filed for regulatory approval in the EU in February 2025, with a subsequent filing in Japan in May 2025. Part 2 of the ESSENCE trial is expected to read out in 2029. About Wegovy® (semaglutide 2.4 mg) The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. Today, the FDA granted accelerated approval for Wegovy® for a new patient population for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Sina Meyer +45 3079 6656 azey@ Frederik Taylor Pitter (US) +1 609 613 0568 fptr@ Max Ung +45 3077 6414 mxun@ Publication of inside information pursuant to Market Abuse Regulation, Article 17. Attachment CA250815-MASH-US-label-update
Fox News
an hour ago
- Fox News
German researchers discover dozens of shipwrecks including possible WWII steamer lost in air raid
German researchers recently announced the discovery of 31 shipwrecks, including a possible steamship that was destroyed in a World War II air raid. The shipwrecks were found in Germany's Lake Constance as part of the "Wrecks and Deep Sea" project. Since the project's launch in 2022, divers and remotely operated vehicles (ROVs) have pinpointed more than 250 potential underwater anomalies, according to a Tuesday news release from the State Office for Monument Preservation. Out of the 186 anomalies investigated so far, 31 have been confirmed as shipwrecks — ranging from historic objects to modern sport boats. The other 155 anomalies wound up being natural formations like plant growth or artificial items like fishing gear, as noted in the release. Among the discoveries were two large metal ship hulls. Due to their location and size, researchers believe they could be the hulls of paddle steamers SD Friedrichshafen II and SD Baden, the news release noted. The SD Friedrichshafen II was destroyed during an air raid in World War II, while the SD Baden was taken out of service in 1930 and ultimately sunk, according to news outlet Arkeonews. "Wrecks are far more than just lost vehicles — they are true time capsules that preserve stories and craftsmanship from long ago" Alexandra Ulisch, a project research associate, said in a statement. Researchers also found a nearly completely preserved cargo sailing ship, which had its mast and yard still intact. The ship's resting place deep underwater helped preserve key features, like bow clamps and belaying pins, by limiting the growth of invasive quagga mussels, as noted in the release. At another site with widely scattered debris, researchers found at least 17 wooden barrels, according to the release. The project will continue through summer 2027. Earlier this year, a vintage car was discovered during a similar underwater excavation of the USS Yorktown in the Pacific Ocean, according to the National Oceanic and Atmospheric Administration (NOAA).
Yahoo
2 hours ago
- Yahoo
Two Men Were Fixing an Antenna in New Jersey—and Accidentally Discovered Proof of the Big Bang
How did we get here? Humanity, life on Earth, our planet itself—how did everything in the universe come into being. Well, as far as we know, it all started with the Big Bang. But while the Big Bang theory has certainly been in place for a while, we didn't always have proof that it occurred. It wasn't until 1964 that scientists managed to capture evidence of the explosion that kickstarted our reality—and explosion we can still hear to this day. The story behind the discovery of the cosmic microwave background—the radiation that originated from the Big Bang and now permeates every corner in the universe—is full of twists and turns, accidents and frustrations, trials and errors, and pigeons (yes, pigeons). But it started with a hypothesis: if the Big Bang really happened, we should still be able to hear the ripples it created. Watch Pop Mech's Jackie Appel reveal the story of how two men from New Jersey named Arno Penzias and Robert Wilson made one of the most important discoveries in the history of astronomy—by accident. Using creativity, grit, and a giant horn-shaped radio telescope, they managed to prove once and for all how our universe originally came to be. The work wasn't easy. There were a lot of false starts and baffling data to sort through, and the duo needed to collaborate with an entirely unrelated research team to eventually reach their world-changing conclusion. But even limited as they were by 1960s tech, they managed to make the discovery of a lifetime. See the full episode and learn more about how Penzias and Wilson changed cosmology forever in the video above. And don't forget to check out the rest of our show Pop Mech Explains the Universe, where we explore other fascinating space stories just like this one. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword
